Nebivolol in Patients With Systolic Stage 2 Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 433 participants.

Also called NCT01057251

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 433 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01057251
Other papers using this trial's data
  • Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial Clinical therapeutics, 2013-02 DOI, PubMed 23332366

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01057251. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2012-01-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Nebivolol in Patients With Systolic Stage 2 Hypertension
Acronym
NEB-MD-20
Condition
Hypertension
Intervention (Drug)
Nebivolol
Intervention (Drug)
Placebo
Lead sponsor
Forest Laboratories (class: industry)

Record details

Record id
cardio:ct-nct01057251
Content hash
a0bf0792228a749b1f77c77352104d0509b45e6704b943db23250be8f618cb93